STAAR Surgical Reports 55% Drop in Q2 2025 Net Sales, Posts $16.8 Million Net Loss, EPS Falls to $(0.34)
Reuters
Aug 07
STAAR Surgical Reports 55% Drop in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Net Sales, Posts $16.8 Million Net Loss, EPS Falls to $(0.34)
STAAR Surgical Company (NASDAQ: STAA) has reported its financial results for the second quarter ending June 27, 2025. The company, known for its EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, recorded net sales of $44.3 million, a 55% decrease year-over-year. This decline was attributed to a planned reduction of channel inventory in China. Excluding China, net sales amounted to $39.0 million, representing a 10% increase year-over-year. The gross margin for the quarter stood at 74.0%, down from 79.2% in the same period last year but an improvement from 65.8% in the first quarter of this year. STAAR Surgical reported a net loss of $16.8 million, compared to a net income of $7.4 million in the previous year. Notably, the company will not host a conference call to review its second quarter results due to its pending acquisition by Alcon Inc.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806269062) on August 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.